MCID: ANP005
MIFTS: 57

Anaplastic Astrocytoma

Categories: Bone diseases, Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Anaplastic Astrocytoma

MalaCards integrated aliases for Anaplastic Astrocytoma:

Name: Anaplastic Astrocytoma 12 20 58 54 17
Grade Iii Astrocytoma 12 20 15
Grade Iii Astrocytic Tumor 12
Astrocytoma, Anaplastic 6

Characteristics:

Orphanet epidemiological data:

58
anaplastic astrocytoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3078
MeSH 44 D001254
NCIt 50 C9477
SNOMED-CT 67 55353007
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0334579
Orphanet 58 ORPHA251589
UMLS 71 C0334579

Summaries for Anaplastic Astrocytoma

GARD : 20 Anaplastic astrocytoma is a rare, cancerous (malignant) type of brain tumor that arises from star-shaped brain cells called astrocytes. These cells surround and protect nerve cells in the brain and spinal cord. An anaplastic astrocytoma usually develops slowly over time, but may develop rapidly. Signs and symptoms vary depending on the location and size of the tumor and may include headaches, drowsiness, vomiting, and changes in personality or mental status. Some affected people have seizures, vision problems, weakness of the limbs, and/or coordination problems. Anaplastic astroctyomas usually occur sporadically but can be associated with a few rare, genetic disorders. Treatment may include surgery, radiation, and/or chemotherapy.

MalaCards based summary : Anaplastic Astrocytoma, also known as grade iii astrocytoma, is related to glioma and malignant astrocytoma. An important gene associated with Anaplastic Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Vincristine and Procarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and endothelial, and related phenotypes are Reduced mammosphere formation and cellular

Disease Ontology : 12 A malignant astrocytoma that is characterized by cells with regular, round to oval nuclei.

Wikipedia : 74 Anaplastic astrocytoma is a rare WHO grade III type of astrocytoma, which is a type of cancer of the... more...

Related Diseases for Anaplastic Astrocytoma

Diseases related to Anaplastic Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 460)
# Related Disease Score Top Affiliating Genes
1 glioma 32.3 TP53 PTEN PDGFRA MDM2 IDH2 IDH1
2 malignant astrocytoma 31.8 VEGFA TP53 PTEN PDGFRA OLIG2 MIR196A1
3 glial tumor 31.7 PTEN OLIG2 EGFR
4 high grade glioma 31.5 VEGFA TP53 PTEN PDGFRA MGMT EGFR
5 glioblastoma 31.4 VEGFA TP53 PTEN PDGFRA MGMT MDM2
6 oligoastrocytoma 31.2 MGMT IDH2 GFAP
7 high-grade astrocytoma 31.2 TP53 PTEN IDH1 ATRX
8 low-grade astrocytoma 31.1 TP53 IDH1 CDKN2A
9 meningioma, familial 31.1 TP73 TP53 PTEN GFAP EGFR CDKN2A
10 low grade glioma 31.0 TP73 MGMT IDH2 IDH1
11 enchondromatosis, multiple, ollier type 31.0 IDH2 IDH1 ATRX
12 adenoma 30.9 TP53 MGMT CDKN2A CCND1
13 hydrocephalus 30.8 VEGFA TP53 PTEN GFAP
14 diffuse astrocytoma 30.8 TP53 OLIG2 MGMT IDH2 IDH1 GFAP
15 leukemia, acute lymphoblastic 30.7 TP73 TP53 PTEN MIR196A1 CDKN2A CDK4
16 myelodysplastic syndrome 30.7 VEGFA TP53 PTEN MGMT MDM2 IDH2
17 pilocytic astrocytoma 30.7 TP53 PTEN OLIG2 MGMT IDH1 GFAP
18 multiple enchondromatosis, maffucci type 30.6 IDH2 IDH1 ATRX
19 medulloblastoma 30.6 VEGFA TP73 TP53 PTEN PDGFRA MGMT
20 plexiform neurofibroma 30.6 TP53 PDGFRA CDKN2A
21 rhabdoid cancer 30.6 TP53 CDKN2A CCND1
22 anaplastic oligodendroglioma 30.6 OLIG2 OLIG1 MGMT IDH2
23 atypical teratoid rhabdoid tumor 30.6 TP53 GFAP CCND1 ATRX
24 neurofibromatosis, type i 30.6 TP53 PTEN PDGFRA OLIG2 MGMT IDH1
25 brain cancer 30.6 VEGFA TP73 TP53 PTEN PDGFRA OLIG2
26 gliomatosis cerebri 30.5 TP53 PTEN MDM2 IDH1 GFAP EGFR
27 pleomorphic xanthoastrocytoma 30.5 TP53 MGMT IDH2 IDH1 GFAP ATRX
28 hemangioblastoma 30.5 VEGFA PDGFRA GFAP EGFR
29 spinal cord astrocytoma 30.5 MGMT IDH1
30 neurofibroma 30.5 VEGFA TP53 PTEN PDGFRA EGFR CDKN2A
31 angiocentric glioma 30.5 IDH1 GFAP
32 diffuse midline glioma, h3 k27m-mutant 30.5 TP53 PDGFRA OLIG2 MGMT IDH1 ATRX
33 li-fraumeni syndrome 30.4 TP53 PTEN MDM2 IDH2 IDH1 EGFR
34 renal cell carcinoma, nonpapillary 30.4 VEGFA TP53 PTEN PDGFRA MIR196A1 EGFR
35 mixed glioma 30.3 TP53 PTEN PDGFRA OLIG2 MGMT IDH2
36 melanoma 30.3 VEGFA TP53 PTEN PDGFRA MGMT MDM2
37 gliosarcoma 30.2 VEGFA TP53 PTEN PDGFRA OLIG2 MGMT
38 leukemia, acute myeloid 30.2 VEGFA TP53 PTEN PDGFRA MIR196A1 MDM2
39 oligodendroglioma 30.0 VEGFA TP73 TP53 PTEN PDGFRA OLIG2
40 glioma susceptibility 1 11.1
41 ring chromosome 7 10.6 TP53 MDM2 CDK4
42 ring chromosome 10.6 TP53 MDM2 CDK4
43 esophageal leukoplakia 10.6 TP53 CCND1
44 undifferentiated embryonal sarcoma of the liver 10.6 TP53 MDM2 CDK4
45 enchondroma 10.6 IDH2 IDH1
46 embryonal sarcoma 10.6 TP53 MDM2 CDK4
47 peripheral osteosarcoma 10.6 TP53 MDM2 CDK4
48 mammary analogue secretory carcinoma 10.6 TP53 EGFR CCND1
49 parameningeal embryonal rhabdomyosarcoma 10.6 TP53 MDM2 CDK4
50 embryonal rhabdomyosarcoma 10.6 TP53 MDM2 CDK4

Graphical network of the top 20 diseases related to Anaplastic Astrocytoma:



Diseases related to Anaplastic Astrocytoma

Symptoms & Phenotypes for Anaplastic Astrocytoma

GenomeRNAi Phenotypes related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 ATRX CCND1 CDK4 EGFR IDH2 MCM3

MGI Mouse Phenotypes related to Anaplastic Astrocytoma:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 ATRX CCND1 CDK4 CDKN2A DMBT1 EGFR
2 growth/size/body region MP:0005378 10.49 ATRX CCND1 CDK4 CDKN2A EGFR GFAP
3 homeostasis/metabolism MP:0005376 10.47 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
4 mortality/aging MP:0010768 10.46 ATRX CCND1 CDK4 CDKN2A DMBT1 EGFR
5 behavior/neurological MP:0005386 10.44 ATRX CCND1 CDK4 CDKN2A GFAP MDM2
6 cardiovascular system MP:0005385 10.44 ATRX CCND1 CDK4 CDKN2A EGFR GFAP
7 digestive/alimentary MP:0005381 10.38 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
8 embryo MP:0005380 10.38 ATRX CDK4 CDKN2A DMBT1 EGFR MCM3
9 endocrine/exocrine gland MP:0005379 10.37 CCND1 CDK4 CDKN2A EGFR MCM3 MDM2
10 immune system MP:0005387 10.37 CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
11 hematopoietic system MP:0005397 10.35 CCND1 CDK4 CDKN2A EGFR IDH1 MCM3
12 neoplasm MP:0002006 10.35 CCND1 CDK4 CDKN2A DMBT1 EGFR IDH2
13 nervous system MP:0003631 10.33 ATRX CCND1 CDK4 CDKN2A EGFR GFAP
14 integument MP:0010771 10.29 CCND1 CDK4 CDKN2A EGFR MCM3 MDM2
15 craniofacial MP:0005382 10.21 CCND1 CDK4 EGFR MDM2 PDGFRA TP53
16 muscle MP:0005369 10.19 CDK4 CDKN2A EGFR GFAP MDM2 OLIG2
17 liver/biliary system MP:0005370 10.13 CDK4 CDKN2A EGFR MCM3 MDM2 PTEN
18 limbs/digits/tail MP:0005371 10.08 EGFR IDH2 MDM2 PDGFRA PTEN TP53
19 normal MP:0002873 10.06 CCND1 CDK4 EGFR GFAP MDM2 PDGFRA
20 no phenotypic analysis MP:0003012 10.03 CDKN2A EGFR MDM2 MGMT OLIG2 PDGFRA
21 reproductive system MP:0005389 10 ATRX CCND1 CDK4 CDKN2A EGFR MDM2
22 renal/urinary system MP:0005367 9.92 CDK4 DMBT1 EGFR MDM2 PDGFRA PTEN
23 pigmentation MP:0001186 9.91 CDK4 CDKN2A EGFR MDM2 PDGFRA PTEN
24 respiratory system MP:0005388 9.9 CCND1 CDKN2A EGFR IDH1 MGMT OLIG2
25 skeleton MP:0005390 9.77 CCND1 CDK4 CDKN2A EGFR IDH1 IDH2
26 vision/eye MP:0005391 9.36 ATRX CCND1 CDK4 CDKN2A EGFR GFAP

Drugs & Therapeutics for Anaplastic Astrocytoma

Drugs for Anaplastic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
2
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
3
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
4
Bevacizumab Approved, Investigational Phase 3 216974-75-3
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Carmustine Approved, Investigational Phase 3 154-93-8 2578
7
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
8
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
9
Semustine Experimental, Investigational Phase 3 13909-09-6
10 Dianhydrogalactitol Investigational Phase 3 23261-20-3
11 Antiparasitic Agents Phase 3
12 Antiprotozoal Agents Phase 3
13 Angiogenesis Inhibitors Phase 2, Phase 3
14 Antineoplastic Agents, Immunological Phase 2, Phase 3
15 Mitogens Phase 3
16 Trabedersen Phase 3
17
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
18
Etoposide Approved Phase 2 33419-42-0 36462
19
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
20
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
21
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
22
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
23
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
24
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
25
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
26
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
27
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
28
Gefitinib Approved, Investigational Phase 1, Phase 2 184475-35-2 123631
29
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
30
Mercaptopurine Approved Phase 2 50-44-2 667490
31
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
32
Piperazine Approved, Vet_approved Phase 1, Phase 2 110-85-0 4837
33
Mebendazole Approved, Vet_approved Phase 1, Phase 2 31431-39-7 4030
34
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
35
Trametinib Approved Phase 2 871700-17-3 11707110
36
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
37
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
38
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
39
Mannitol Approved, Investigational Phase 1, Phase 2 69-65-8 453 6251
40
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
41
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
42
Boron Experimental Phase 1, Phase 2 7440-42-8 5460517
43 Talaporfin Investigational Phase 2 110230-98-3
44 Molgramostim Investigational Phase 2 99283-10-0
45 Etirinotecan pegol Investigational Phase 2 848779-32-8
46
Veliparib Investigational Phase 2 912444-00-9 11960529
47
Imetelstat Investigational Phase 2 868169-64-6
48 Anticonvulsants Phase 2
49 Etoposide phosphate Phase 2
50 Albumin-Bound Paclitaxel Phase 2

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
3 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
4 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
5 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
6 A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3) Terminated NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
7 Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study. Terminated NCT00761280 Phase 3 trabedersen;temozolomide;carmustine;lomustine
8 A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma Terminated NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
9 A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Withdrawn NCT04105374 Phase 2, Phase 3 Extended Release Flucytosine;Temozolomide
10 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
11 BPA-Mediated Boron Neutron Capture Therapy (BNCT) in the Treatment of Glioblastoma or Anaplastic Astrocytoma Progressing After Conventional External Beam Radiotherapy Completed NCT00115440 Phase 1, Phase 2
12 Pilot Study to Determine Therapeutic Response of Oral Capecitabine (Xeloda) in Recurrent High Grade Gliomas (HGGs) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria Completed NCT00717197 Phase 2 Capecitabine
13 Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma) Completed NCT00003621 Phase 2 carmustine;cisplatin;etoposide
14 Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma Completed NCT00003537 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
15 Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma Completed NCT00003470 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
16 A Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma (Defined for the Purposes of the Protocol as Anaplastic Astrocytoma [AA] or Glioblastoma Multiforme [GBM]) Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma Completed NCT00409214 Phase 2 LS11 (talaporfin sodium)
17 A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma Completed NCT00002814 Phase 2 paclitaxel;topotecan hydrochloride
18 A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse Completed NCT00003775 Phase 2 leflunomide
19 A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme Completed NCT00606008 Phase 2 Sunitinib Malate
20 Phase I/II Trial of Oral Erlotinib (Tarceva, OSI-774) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma Completed NCT00301418 Phase 1, Phase 2 Erlotinib
21 A Phase II Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme Completed NCT00921167 Phase 2 Bevacizumab/Irinotecan
22 SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma Completed NCT00783393 Phase 2 Temozolomide
23 Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma Completed NCT02942264 Phase 1, Phase 2 Zotiraciclib (TG02);TMZ
24 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
25 A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2 depsipeptide
26 Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
27 A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas Completed NCT00045708 Phase 1, Phase 2 ixabepilone;Anticonvulsant
28 Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors Completed NCT00042991 Phase 1, Phase 2 gefitinib
29 A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients Completed NCT01462695 Phase 2 Sunitinib Malate
30 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
31 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
32 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
33 Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Completed NCT00369590 Phase 2
34 Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
35 A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG) Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
36 Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naive Patients With Recurrent Glioblastoma Multiforme Completed NCT01648348 Phase 1, Phase 2
37 A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma) Completed NCT00823797 Phase 2 Bendamustine Hydrochloride
38 A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
39 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
40 A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
41 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
42 Everfront Biotech Co., Ltd. Recruiting NCT03234595 Phase 1, Phase 2 Cerebraca wafer
43 A Phase II Trial of Low Dose Fractionated Radiation Therapy as a Chemo-Potentiator of Salvage Temozolomide for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme Recruiting NCT01466686 Phase 2 Temozolomide
44 Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab (Avastin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma. Recruiting NCT01269853 Phase 1, Phase 2 Bevacizumab;Bevacizumab
45 Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma Recruiting NCT02800486 Phase 2 Intra-arterial Cetuximab;Intra-arterial Mannitol
46 Phase I-II Study Evaluating HSV-tK + VALACYCLOVIR GENE THERAPY Combination With Radiotherapy and Chemotherapy for Newly Diagnosed Anaplastic Astrocytoma and Glioblastoma Multiforme. Recruiting NCT03603405 Phase 1, Phase 2 ADV/HSV-tk (gene therapy)
47 A Phase 1, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Central Nervous System (CNS) Penetration of CC-90010 in Preoperative Subjects With Progressive or Recurrent Who Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and Recurrent Glioblastoma Scheduled for Resection Recruiting NCT04047303 Phase 1, Phase 2 CC-90010
48 A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations Recruiting NCT03581292 Phase 2 Temozolomide;Veliparib
49 Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification) Recruiting NCT04623931 Phase 2 Temozolomide
50 A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) Recruiting NCT03919071 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide

Search NIH Clinical Center for Anaplastic Astrocytoma

Genetic Tests for Anaplastic Astrocytoma

Anatomical Context for Anaplastic Astrocytoma

MalaCards organs/tissues related to Anaplastic Astrocytoma:

40
Brain, Spinal Cord, Endothelial, Eye, Bone Marrow, Cerebellum, Temporal Lobe

Publications for Anaplastic Astrocytoma

Articles related to Anaplastic Astrocytoma:

(show top 50) (show all 2140)
# Title Authors PMID Year
1
Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. 61 54
20090216 2010
2
Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma. 61 54
19876867 2009
3
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. 54 61
19512898 2009
4
Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. 61 54
18795327 2009
5
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. 61 54
19346643 2009
6
Mutational inactivation of the nijmegen breakage syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations. 54 61
19151620 2009
7
Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. 61 54
19657395 2009
8
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. 61 54
18945611 2009
9
FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. 61 54
18974115 2008
10
PTEN signaling pathways in glioblastoma. 54 61
18836294 2008
11
Serum GFAP is a diagnostic marker for glioblastoma multiforme. 61 54
17998256 2007
12
Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. 54 61
17404569 2007
13
Concurrent EGFR amplification and TP-53 mutation in glioblastomas. 54 61
17907599 2007
14
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. 54 61
17721049 2007
15
Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. 61 54
17679463 2007
16
Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. 54 61
17415208 2007
17
Molecular pathogenesis of pediatric astrocytic tumors. 61 54
17327574 2007
18
O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. 61 54
16849758 2006
19
Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. 54 61
16818615 2006
20
Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas. 54 61
16614947 2006
21
Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. 61 54
16618782 2006
22
Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology. 54 61
16150117 2005
23
Apolipoprotein D expression in primary brain tumors: analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue. 54 61
16055749 2005
24
Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. 61 54
15994925 2005
25
Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma. 54 61
15973775 2005
26
Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. 61 54
16030116 2005
27
Apoptosis and proliferation: correlation with p53 in astrocytic tumours. 54 61
15981097 2005
28
Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. 54 61
15671553 2005
29
Brainstem gliomas--a clinicopathological study of 45 cases with p53 immunohistochemistry. 54 61
15659871 2004
30
Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. 61 54
12939468 2003
31
Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. 61 54
12968803 2003
32
Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. 61 54
12777082 2003
33
Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. 61 54
12700122 2003
34
Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis. 61 54
12702589 2003
35
Molecular genetic analysis of phosphatase and tensin homolog and p16 tumor suppressor genes in patients with malignant glioma. 61 54
15679305 2003
36
Recurrent astrocytic tumours--a study of p53 immunoreactivity and malignant progression. 61 54
12389885 2002
37
Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. 61 54
11958417 2002
38
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. 54 61
11683943 2001
39
Elevated levels of cathepsin B in human glioblastoma cell lines. 61 54
11494030 2001
40
[A case of glioblastoma associated with dissemination, secondary to intratumoral hemorrhage]. 61 54
11554096 2001
41
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. 54 61
11504770 2001
42
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. 54 61
11431323 2001
43
Characterisation of molecular alterations in microdissected archival gliomas. 61 54
11355303 2001
44
Comparison of cyclin A and MIB-1 expression in astrocytic tumors using image-based cell analysis system. 61 54
11277408 2001
45
Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. 61 54
11234878 2001
46
Expression of hepatocyte growth factor and matrix metalloproteinase-2 in human glioma. 54 61
11517976 2001
47
Regulation of the uPA gene in various grades of human glioma cells. 54 61
11115541 2001
48
Promoter hypermethylation of the RB1 gene in glioblastomas. 54 61
11204276 2001
49
Molecular genetic analysis of archival gliomas using diagnostic smears. 61 54
11054184 2000
50
Functional evaluation of p53 and PTEN gene mutations in gliomas. 54 61
11051241 2000

Variations for Anaplastic Astrocytoma

ClinVar genetic disease variations for Anaplastic Astrocytoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Pathogenic 12364 rs28934574 17:7577094-7577094 17:7673776-7673776
2 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
3 ATRX NM_000489.5(ATRX):c.5579A>G (p.Asn1860Ser) SNV Pathogenic 11724 rs45439799 X:76856021-76856021 X:77600552-77600552

Expression for Anaplastic Astrocytoma

Search GEO for disease gene expression data for Anaplastic Astrocytoma.

Pathways for Anaplastic Astrocytoma

Pathways related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 VEGFA TP53 PTEN PDGFRA MDM2 EGFR
2
Show member pathways
13.04 VEGFA TP53 PTEN PDGFRA MDM2 EGFR
3
Show member pathways
12.99 VEGFA TP53 PDGFRA MDM2 EGFR CDKN2A
4
Show member pathways
12.83 TP73 TP53 MDM2 CDK4 CCND1
5
Show member pathways
12.83 VEGFA TP53 PTEN PDGFRA MDM2 EGFR
6
Show member pathways
12.82 TP53 PTEN EGFR CDKN2A CDK4 CCND1
7 12.78 VEGFA TP53 PTEN PDGFRA MDM2 EGFR
8
Show member pathways
12.74 TP53 PTEN PDGFRA MDM2 EGFR
9
Show member pathways
12.71 TP53 MGMT MDM2 CDK4 CCND1
10
Show member pathways
12.68 TP53 PTEN PDGFRA MDM2 EGFR CDKN2A
11
Show member pathways
12.67 VEGFA TP53 PTEN PDGFRA MDM2 EGFR
12
Show member pathways
12.64 TP53 MDM2 MCM3 CDKN2A CDK4 CCND1
13
Show member pathways
12.55 VEGFA TP53 PTEN MDM2 EGFR
14 12.46 VEGFA TP53 PTEN PDGFRA MDM2 EGFR
15
Show member pathways
12.45 TP53 PDGFRA MDM2 EGFR
16 12.44 TP53 MDM2 MCM3 CDKN2A CDK4 CCND1
17
Show member pathways
12.42 PDGFRA GFAP EGFR CCND1
18
Show member pathways
12.41 TP73 TP53 PTEN MDM2 CDKN2A CDK4
19
Show member pathways
12.4 TP53 PTEN MDM2 CCND1
20 12.4 TP53 PTEN CDKN2A CDK4 CCND1
21 12.39 TP73 TP53 MGMT MDM2 MCM3 CDKN2A
22
Show member pathways
12.38 TP53 PTEN MDM2 EGFR CCND1
23
Show member pathways
12.36 TP53 CDKN2A CDK4 CCND1
24 12.36 VEGFA TP53 MDM2 EGFR CCND1
25 12.36 TP53 MDM2 CDKN2A CDK4 CCND1
26
Show member pathways
12.31 TP53 PTEN MDM2 CDK4 CCND1
27
Show member pathways
12.28 TP53 PTEN PDGFRA MDM2 EGFR CDK4
28 12.21 VEGFA TP53 EGFR CCND1
29 12.19 TP53 PTEN MDM2 CDKN2A CDK4 CCND1
30 12.15 TP73 TP53 PTEN MDM2 EGFR
31
Show member pathways
12.13 PTEN MDM2 EGFR CCND1
32 12.09 TP53 GFAP EGFR CDK4 CCND1
33 12.01 TP53 PTEN MDM2 CDKN2A
34 11.99 TP73 TP53 PTEN MDM2 CDKN2A CCND1
35 11.99 VEGFA TP53 PTEN MDM2 EGFR CDK4
36 11.94 TP53 PTEN CDK4 CCND1
37 11.93 PTEN MDM2 EGFR CCND1
38 11.92 TP53 MDM2 MCM3 CDK4 CCND1
39 11.85 VEGFA PDGFRA OLIG2 OLIG1 GFAP
40
Show member pathways
11.84 TP73 TP53 MDM2
41
Show member pathways
11.76 TP53 MDM2 CDKN2A
42 11.75 TP53 MDM2 CDKN2A
43
Show member pathways
11.73 VEGFA EGFR CCND1
44 11.73 VEGFA TP53 MDM2 CDKN2A
45 11.7 TP53 PTEN ATRX
46 11.67 VEGFA TP53 MDM2 CDKN2A
47 11.67 TP53 PTEN MDM2 CCND1
48 11.62 PDGFRA CDK4 CCND1
49 11.62 TP53 PDGFRA EGFR CDKN2A CCND1
50 11.59 TP53 PTEN MDM2 CDK4

GO Terms for Anaplastic Astrocytoma

Cellular components related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.1 TP73 TP53 PTEN PDGFRA OLIG2 OLIG1
2 nucleoplasm GO:0005654 9.9 TP73 TP53 PTEN PDGFRA MGMT MDM2
3 cytoplasm GO:0005737 9.5 VEGFA TP73 TP53 PTEN PDGFRA OLIG2
4 protein-containing complex GO:0032991 9.43 TP53 PDGFRA MDM2 EGFR CDKN2A CDK4

Biological processes related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.15 VEGFA TP73 TP53 MDM2 EGFR CDKN2A
2 cellular response to DNA damage stimulus GO:0006974 10.04 TP73 TP53 MGMT CCND1 ATRX
3 positive regulation of gene expression GO:0010628 10.04 VEGFA TP53 PTEN MDM2 CDKN2A
4 cell cycle GO:0007049 10.04 TP73 TP53 MCM3 CDKN2A CDK4 CCND1
5 viral process GO:0016032 10.01 TP73 TP53 PDGFRA MDM2 EGFR DMBT1
6 positive regulation of apoptotic process GO:0043065 9.97 TP73 TP53 PTEN CDKN2A CDK4
7 negative regulation of apoptotic process GO:0043066 9.93 VEGFA TP53 PTEN MGMT MDM2 EGFR
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 VEGFA PTEN PDGFRA EGFR
9 regulation of cell cycle GO:0051726 9.86 TP53 PTEN CDK4 CCND1
10 response to organic substance GO:0010033 9.84 PTEN CDK4 CCND1
11 circadian rhythm GO:0007623 9.83 TP53 EGFR CDK4
12 cellular response to hypoxia GO:0071456 9.83 VEGFA TP53 PTEN MDM2
13 negative regulation of neuron projection development GO:0010977 9.8 PTEN MDM2 GFAP
14 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.79 PTEN CDKN2A CDK4
15 positive regulation of cell cycle GO:0045787 9.72 MDM2 CDK4 CCND1
16 positive regulation of cell proliferation GO:0008284 9.7 VEGFA PTEN PDGFRA MDM2 EGFR CDK4
17 amyloid fibril formation GO:1990000 9.66 MDM2 CDKN2A
18 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.65 TP53 EGFR
19 Leydig cell differentiation GO:0033327 9.64 PDGFRA CCND1
20 NADP metabolic process GO:0006739 9.63 IDH2 IDH1
21 mitotic G1 DNA damage checkpoint GO:0031571 9.62 TP53 CCND1
22 G1/S transition of mitotic cell cycle GO:0000082 9.62 MCM3 CDKN2A CDK4 CCND1
23 positive regulation of cell cycle arrest GO:0071158 9.61 TP73 TP53 CDKN2A
24 cellular response to UV-C GO:0071494 9.6 TP53 MDM2
25 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.59 VEGFA TP53
26 isocitrate metabolic process GO:0006102 9.58 IDH2 IDH1
27 response to steroid hormone GO:0048545 9.58 MDM2 IDH1 CCND1
28 cellular response to actinomycin D GO:0072717 9.51 TP53 MDM2
29 response to UV-A GO:0070141 9.49 EGFR CCND1
30 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.48 VEGFA PDGFRA
31 negative regulation of cell cycle arrest GO:0071157 9.43 MDM2 CDK4 CCND1
32 glyoxylate cycle GO:0006097 9.37 IDH2 IDH1
33 response to organic cyclic compound GO:0014070 9.35 PTEN MGMT IDH1 EGFR CCND1
34 response to drug GO:0042493 9.17 TP73 TP53 PTEN MGMT MDM2 CDK4

Molecular functions related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.06 VEGFA TP73 TP53 PTEN OLIG2 MDM2
2 enzyme binding GO:0019899 9.85 TP53 PTEN MDM2 EGFR CCND1
3 protein kinase binding GO:0019901 9.85 TP73 TP53 PTEN EGFR CDKN2A CCND1
4 disordered domain specific binding GO:0097718 9.61 TP53 MDM2 CDKN2A
5 p53 binding GO:0002039 9.46 TP73 TP53 MDM2 CDKN2A
6 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.32 IDH2 IDH1
7 isocitrate dehydrogenase activity GO:0004448 9.26 IDH2 IDH1
8 platelet-derived growth factor receptor binding GO:0005161 9.13 VEGFA PTEN PDGFRA
9 MDM2/MDM4 family protein binding GO:0097371 8.8 TP73 TP53 CDKN2A

Sources for Anaplastic Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....